Table 3 TNF-α and CCR5Δ32 genotype and allele frequencies in the different subsets of HIV-1-infected patients for assessment of associations with disease progression.
Genotype and allele frequencies | HIV-1 TP (n = 109) | HIV-1 LTNP (n = 75) | pvalue * | HIV-1 LNTP-DVL (n = 55) | HIV-1 LTNP-EC (n = 20) | pvalue ** |
|---|---|---|---|---|---|---|
TNF-α-238G>A | ||||||
GG | 97 (90%) | 64 (85.3%) | 50 (90.9%) | 14 (70%) | ||
GA | 11 (10%) | 11 (14.7%) | 0.35 | 5 (9.1%) | 6 (30%) | 0.02 |
AA | 1 (1%) | 0 | 0 | 0 | ||
GA+AA | 12 (11%) | 11 (14.7%) | 0.6 | 5 (9.1%) | 6 (30%) | 0.02 |
Variant allele A | 13 (6%) | 11 (7.3%) | 0.7 | 5 (4.5%) | 6 (15%) | 0.03 |
TNF-α-308 G>A | ||||||
GG | 86 (78.9%) | 62 (82.7%) | 46 (83.6%) | 16 (80%) | ||
GA | 20 (18.3%) | 11 (14.7%) | 0.7 | 8 (14.5%) | 3 (15%) | 0.7 |
AA | 3 (2.8%) | 2 (2.6%) | 1 (1.9%) | 1 (5%) | ||
GA+AA | 23 (21.1%) | 13 (17.3%) | 0.5 | 9 (16.4%) | 4 (20%) | 0.7 |
Variant allele A | 26 (11.9%) | 15 (10%) | 0.6 | 10 (9.1%) | 5 (12.5%) | 0.7 |
TNF-α-863 C>A | ||||||
CC | 84 (77.1%) | 53 (70.6%) | 37 (67.3%) | 16 (80%) | ||
CA | 25 (22.9%) | 20 (26.6%) | 0.2 | 17 (30.9%) | 3 (15%) | 0.3 |
AA | 0 | 2 (2.8%) | 1 (1.8%) | 1 (5%) | ||
CA+AA | 25 (22.9%) | 22 (29.3%) | 0.4 | 18 (32.7%) | 4 (20%) | 0.3 |
Variant allele A | 25 (11.5%) | 24 (16%) | 0.2 | 19 (17.3%) | 5 (12.5%) | 0.4 |
CCR5Δ32 | ||||||
wt/wt | 88 (80.7%) | 57 (76%) | 39 (70.9%) | 18 (90%) | ||
wt/Δ32 | 21 (19.3%) | 18 (24%) | 0.4 | 16 (29.1%) | 2 (10%) | 0.1 |
Δ32/Δ32 | 0 | 0 | 0 | 0 | ||
Variant allele Δ32 | 21 (9.6%) | 18 (12%) | 0.5 | 16 (14.5%) | 2 (5%) | 0.1 |